MacroPore Biosurgery, Inc. (Frankfurt:XMP) announced
today it will release financial results for the first quarter on
Thursday, May 12, 2005 at approximately 3:30 p.m. Central European
Summer Time (CEST) or 9:30 a.m. Eastern Daylight Time (EDT). The
company's management will host a conference call at 4:00 p.m. (CEST)
or 10:00 a.m. (EDT) to discuss the results.
The conference call will be webcast live and may be accessed under "Webcasts" in the Investor Relations section of the Company's website at http://www.macropore.com. The webcast will be available 60 Minutes after the call on the company's website and archived for 90 days. A telephone replay will be available for one week. To access the replay, please call +1 (303) 590-3000 (PIN: 11030145#) or +49 (0) 69-58 99 90 568 (PIN: 133186#).
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery specializes in the discovery and development of regenerative medicine therapies. The Company has two principal technology platforms, adipose-derived regenerative cells and bioresorbable implants. The Company is developing treatments for cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery using stem and regenerative cells from adipose tissue. This tissue is the richest and most accessible known source for regenerative cells. To facilitate the processing and delivery of adipose-derived regenerative cells, the Company is designing a proprietary point-of-care system, Celution(TM), to isolate and concentrate a patient's own regenerative cells in real-time. Additionally, MacroPore Biosurgery manufactures the HYDROSORB(TM) family of FDA-cleared bioresorbable spine and orthopedic implants, which are distributed exclusively through Medtronic, Inc. For more information, please visit http://www.macropore.com.
The conference call will be webcast live and may be accessed under "Webcasts" in the Investor Relations section of the Company's website at http://www.macropore.com. The webcast will be available 60 Minutes after the call on the company's website and archived for 90 days. A telephone replay will be available for one week. To access the replay, please call +1 (303) 590-3000 (PIN: 11030145#) or +49 (0) 69-58 99 90 568 (PIN: 133186#).
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery specializes in the discovery and development of regenerative medicine therapies. The Company has two principal technology platforms, adipose-derived regenerative cells and bioresorbable implants. The Company is developing treatments for cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery using stem and regenerative cells from adipose tissue. This tissue is the richest and most accessible known source for regenerative cells. To facilitate the processing and delivery of adipose-derived regenerative cells, the Company is designing a proprietary point-of-care system, Celution(TM), to isolate and concentrate a patient's own regenerative cells in real-time. Additionally, MacroPore Biosurgery manufactures the HYDROSORB(TM) family of FDA-cleared bioresorbable spine and orthopedic implants, which are distributed exclusively through Medtronic, Inc. For more information, please visit http://www.macropore.com.